This article is more than 5 years old. Information may no longer be current.
Pure-Vu cleanses inadequately prepared colons during procedures
The Pure-Vu System, an FDA-approved device that fits onto the end of a colonoscope, allowed for effective and safe in-procedure cleansing of inadequately prepared colons, according to research published in the Journal of Clinical Gastroenterology.
In a press release issued by the device’s manufacturer, Motus GI, Javier Pérez Jiménez, MD, medical director for San Rafael Hospital in Cadiz, Spain, said data from the study included encouraging physician and patient-reported outcomes.
“The Pure-Vu System has the potential to play a key role in enhancing the colonoscopy procedure's effectiveness in multiple patient populations,” he said in the release. “The ability to improve the patient's experience and the overall quality of the exam is an area of great importance as inadequate preparation can lead to increased rates of missed lesions, earlier repeat procedures, prolonged colonoscopy duration, reduced patient satisfaction and increased costs.”
Researchers tested the device in a prospective study comprising 50 patients (64% male; mean age, 51.9±10.4 years) at centers in Spain and Israel. Prior to undergoing colonoscopy, patients took a split dose of two tablets of 5 mg of Dulcolax (Sanofi) and had dietary restrictions as a partial preparation for the procedure.
Investigators assessed the device’s safety and improvement of colon cleansing level using the Boston Bowel Preparation Score (BBPS).
Prior to cleansing with Pure-Vu, 31% of patients had an adequate cleansing level, defined as a BBPS of at least 2 in each colon segment. The percentage of patients with adequate scores increased to 98% after endoscopists used the Pure-Vu System (P < .001).
No serious adverse events were reported during the study.
“The Pure-Vu System has consistently shown its ability to improve clinical outcomes while reducing the dependency on conventional purgative-based bowel preps,” Tim Moran, CEO of Motus GI, said in the release. “The data also further supports our confidence in the Pure-Vu System’s ability to successfully cleanse the colon and reduce the number of failed and repeat procedures. It will continue to be an important focus for us to generate clinical and health economic data that we believe will help drive adoption when we officially launch later this year.” – by Alex Young
Disclosures: Pérez Jiménez reports no relevant financial disclosures. Please see the full study for all other authors’ relevant financial disclosures. Moran is employed by Motus GI.